Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endoscopic injection of gelatin solution for severe hemorrhagic gastric cancer.
Tajika M, Kato T, Nagaki M, Kato M, Fukutomi Y, Ninomiya M, Moriwaki H, Saio M, Yamada T, Takami T, Muto Y. Tajika M, et al. Among authors: saio m. Gastrointest Endosc. 1996 Mar;43(3):247-50. doi: 10.1016/s0016-5107(96)70326-7. Gastrointest Endosc. 1996. PMID: 8857144 Review. No abstract available.
Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H. Tsurumi H, et al. Among authors: saio m. J Cancer Res Clin Oncol. 2004 Feb;130(2):107-13. doi: 10.1007/s00432-003-0508-9. Epub 2003 Nov 27. J Cancer Res Clin Oncol. 2004. PMID: 14648210 Clinical Trial.
Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M, Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Kojima Y, et al. Among authors: saio m. Eur J Haematol. 2006 Jun;76(6):465-72. doi: 10.1111/j.1600-0609.2006.00631.x. Epub 2006 Feb 23. Eur J Haematol. 2006. PMID: 16494623 Free article.
Critical role of CD44 in hepatotoxin-mediated liver injury.
Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Kimura K, et al. Among authors: saio m. J Hepatol. 2008 Jun;48(6):952-61. doi: 10.1016/j.jhep.2008.01.033. Epub 2008 Mar 11. J Hepatol. 2008. PMID: 18395288
Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.
Kimura K, Ikoma A, Shibakawa M, Shimoda S, Harada K, Saio M, Imamura J, Osawa Y, Kimura M, Nishikawa K, Okusaka T, Morita S, Inoue K, Kanto T, Todaka K, Nakanishi Y, Kohara M, Mizokami M. Kimura K, et al. Among authors: saio m. EBioMedicine. 2017 Sep;23:79-87. doi: 10.1016/j.ebiom.2017.08.016. Epub 2017 Aug 19. EBioMedicine. 2017. PMID: 28844410 Free PMC article. Clinical Trial.
Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Kimura K, et al. Among authors: saio m. EBioMedicine. 2022 Jun;80:104069. doi: 10.1016/j.ebiom.2022.104069. Epub 2022 May 20. EBioMedicine. 2022. PMID: 35605429 Free PMC article. Clinical Trial.
120 results